Sildenafil increases the force of right atrial contractions in vitro via the NO-guanylyl cyclase pathway involving β-adrenoceptor linked mechanisms

Pharmacological Reports

Volumn 61, Issue 6, 2009, Pages 1146-1152

  Kanoo, Sadhana ^a   Deshpande, Shripad B ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

cGMP; Diltiazem; L NAME; Methylene blue; Phosphodiesterase 5A inhibitor; Propranolol

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL L TYPE; DILTIAZEM; GUANYLATE CYCLASE; GUANYLATE CYCLASE INHIBITOR; METHYLENE BLUE; NITRIC OXIDE SYNTHASE INHIBITOR; N[(]G[)] NITROARGININE METHYL ESTER; PROPRANOLOL; SILDENAFIL; UNCLASSIFIED DRUG;

ADULT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HEART ATRIUM CONTRACTION; HEART MUSCLE CONTRACTILE FORCE; HEART MUSCLE CONTRACTILITY; HEART RATE; HEART RIGHT ATRIUM; HUMAN; IN VITRO STUDY; ISOLATED HEART; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; RAT;

EID: 76049113791     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70177-X     Document Type: Article

References (28)

1. Alex AB, Kanoo S, Deshpande SB: Estrogen modulates in vitro atrial bradycardia induced by Indian red scorpion venom via G-protein coupled mechanisms. Eur J Pharmacol, 2006, 546, 102-108.
2. Dishy V, Sofowora G, Harris PA, Kandcer M, Zhan F, Wood AJ, Stein CM: The effect of sildenafil on nitricoxide mediated vasodilation in healthy men. Clin Pharmacol Ther, 2001, 70, 270-279.
3. Du Toit EF, Rossouw E, Salie R, Opie LH, Lochner A: Effect of sildenafil on reperfusion function, infarct size and cyclic nucleotide levels in the isolated rat heart model. Cardiovasc Drug Ther, 2005, 19, 23-31.
4. Friebe A, Koesling D: Regulation of nitric oxidesensitive guanylyl cyclase. Circ Res, 2003, 93, 96-105.
5. Garg N, Sharma SK, Sinha N: Role of oral sildenafil in severe pulmonary arterial hypertension: Clinical efficacy and dose response relationship. Int J Cardiol, 2007, 20, 306-313.
6. Gonzalez DR, Ignacio CF, Ordenes PP, Treuer AV, Eller G, Boric MP: Differential role of S-nitrosylation and the NO-cGMP-PKG pathway in cardiac contractility. Nitric Oxide, 2008, 18, 157-167.
7. Guazzi M, Samaja M: The role of PDE 5-inhibitors in cardiopulmonary disorders from basic evidence to clinical development. Curr Med Chem, 2007, 14, 2181-2191.
8. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD: The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol, 2004, 44, 2339-2348.
9. Kojda G: Mechanisms of inotropic effects induced by nitric oxide. Ital Heart J Suppl, 2001, 3, 48S-49S.
10. Kojda G, Kottenberg K: Regulation of basal myocardial function by NO. Cardiovasc Res, 1999, 41, 514-523.
11. Kojda G, Kottenberg K, Nix P, Schluter KD, Piper HM, Noack E: Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocytes. Circ Res, 1996, 78, 91-101.
12. Kulkarni SK, Patil CS: Phosphodiesterase 5 enzyme and its inhibitors: update on pharmacological and therapeutical aspects. Methods Find Exp Clin Pharmacol, 2004, 26, 789-799.
13. Langer M, Luttecke D, Schluter K: Mechanism of the positive contractile effect of nitric oxide on rat ventricular cardiomyocytes with positive force/frequency relationship. Pflugers Arch, 2003, 447, 289-297.
14. Lepore JJ, Maroo A, Bigatello LM, Dec GW, Zapol WM, Bloch KD, Semigran MJ: Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest, 2005, 127, 1647-1653.
15. Mohan P, Brutsaert DL, Paulus WJ, Sys SU: Myocardial contractile response to nitric oxide and cGMP. Circulation, 1996, 93, 1223-1229.
16. Nagayama T, Zhang M, Hsu S, Takimoto E, Kass, DA: Sustained soluble guanylate cyclase stimulation offsets NOS inhibition to restore acute cardiac modulation by sildenafil. J Pharmacol Exp Ther, 2008, 326, 380-387.
17. ATP channels in rabbit. Am J Physiol Heart Circ Physiol, 2002, 283, H1263-1269.
18. + exchanger blockade and protection against myocardial infarction. Hypertension, 2007, 49, 1095-1103.
19. Phillips BG, Kato M, Pesek CA, Winnicki M, Narkiewicz K, Davison D, Somers VK: Sympathetic activation by sildenafil. Circulation, 2000, 102, 3068-3073.
20. Rastaldo R, Pagliaro P, Cappello S, Penna C, Mancardi D, Westerhof N, Losano G: Nitric oxide and cardiac function. Life Sci, 2007, 81, 779-793.
21. Reffelmann T, Kloner RA: Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation. Cardiovasc Res, 2003, 59, 441-449.
22. ATP channels when admininstered at reperfusion following ischemia in rabbits. J Mol Cell Cardiol, 2007, 42, 453-458.
23. Senzaki H, Smith CJ, Juang GJ, Isoda T, Mayer SP, Ohler A, Paolocci N et al.: Cardiac phosphodiesterase 5 (cGMP-specific) modulates β-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J, 2001, 15, 1718-1726.
24. Takimoto E, Belardi D, Tocchetti CG, Vahebi S, Cormaci G, Elizabeth AK, Moens AL et al.: Compartmentalization of cardiac β-adrenergic inotropy modulation by phosphodiesterase type 5. Circulation, 2007, 115, 2159-2167.
25. Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Mergia E, Montrose DC et al.: cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res, 2005, 96,100-109.
26. Uthayathas S, Karuppagounder SS, Thrash BM, Parameshwaran K, Suppiramaniam V, Dhanasekaran M: Versatile effects of sildenafil: recent pharmacological applications. Pharmacol Rep, 2007, 59, 150-163.
27. Vila-Petroff MG, Younes A, Egan J, Lakatta EG, Sollott SJ: Activation of distinct cAMP-dependent and cGMPdependent pathways by nitric oxide in cardiac myocytes. Circ Res, 1999, 84, 1020-1031.
28. Yamada M, Inanobe A, Kurachi Y: G-protein regulation of potassium ion channels. Pharmacol Rev, 1998, 50, 723-760.